简介：ＦａｖｏｒａｂｌｅＣｏｎｄｉｔｉｏｎｓ￥ＥｘｐｅｒｔｓｂｅｌｉｅｖｅＴｉｂｅｔｉｓｉｎａｐｏｓｉｔｉｏｎｔｏｔａｋｅｔｈｅｌｅａｄｉｎＣｈｉｎａａｎｄｔｈｅｗｏｒｌｄａｔｌａｒｇｅｔｏｍａｉｎｔａｉｎａｃｏｏｒｄｉｎａｔｅｄｄｅｖｅｌｏｐｍｅｎｔｏｆ...

简介：IwilldiscussthecurrentinternationalenvironmentChinaisfacingfromthefollowingthreeaspects:First,itisnecessarytocalmlyandobiectivelyevaluateothercountries’attitudetowardChinabecausethisinvolvestheirChinapolicy

简介：AgroupofCanadianphysiciansreportssuccessinthelong-termcontroloftreatment-resistantdepressionbyusingdeepbrainstimulation,buttheyacknowledgethatlongerandlargertrialsarestillneeded.

简介：

简介：男富饶上的精索静脉曲张修理的效果仍然保持争论。它将对有用决定了哪个人将从精索静脉曲张修理有益于大多数，并且在那些个人指向修理努力。为精索静脉曲张修理的预示的因素上的文学的详细评论用PubMedNLM数据库被执行。我们发现postvaricocelectomy精液参数的最好的预言者是外科手术前的精液参数。在精液参数的最大的改进与更大的精索静脉曲张在人被发现。当有争吵，更高的睾丸激素，更年轻的年龄和更大的睾丸尺寸时，在一些，研究在精液参数postvaricocelectomy为改进预言。一张诺模图被开发了基于外科手术前的精液参数，精索静脉曲张等级和这个人(www.fertilitytreatmentresults.com)的年龄预言postvaricocelectomy精液参数。有限数据一致地与更高的基线DNA破碎率在人处于DNA破碎率表明最大的改进。关于繁殖结果，更高的基线精子密度一致地为自然怀孕或帮助繁殖技术(艺术)怀孕率预言。另外，精索静脉曲张修理确实似乎为艺术的更侵略的形式减少需要。在结论，我们现在能开始使用象预言跟随varicocelectomy的修理以后的精液质量和富饶潜力的基线精液质量，精索静脉曲张等级和耐心的年龄那样的特定的参数。

简介：1.ObjectivesSouthernQinghai-northemTibetpermafrostregionisaplacehavingthemostwidespreadandmostdevelopedpermafrostinChinawithgoodmineralizationconditionsandprospectingpotentialsforgashydrate(ZhuYHetal.,2011).In2011,ChinaGeologicalSurveyinitiatedaspecialnationalprogramentitled"Gashydrateresourceexplorationandtrialmining",whichsignaledapreludetoacomprehensivegashydratesurveyinsouthernQinghai-northernTibetpermafrostregion.Sofar,appreciableprogresshasbeenmadeinthegeological,geophysical,geochemicalanddrillingsurveyacrossanumberofkeyblocks.Thispaperisintendedtoexaminethefundamentalconditionsforgashydratemineralizationbasedonpreviousfindings,delineatefavorablezonesforgashydratemineralization,andtomakecontributionstotheonshoregashydrateresourceexplorationinChina.

简介：

简介：Infantswithcongenitaldeafnesscausedbyseverebilateralinnerearmalformationsfrequentlysufferfromseverehearinglossandpoorbalance.Unfortunately,theuseofhearingaidsisusuallyineffectiveinrecoveringhearing,necessitatingcochlearimplants.Wereportacaseofa6-year-oldboywithcongenitaldeafnessandbilateralinnerearmalformations(rightside,incompletepartitiontypeI[IP-I];leftside,commoncavitydeformity).Hearingaidshadaremarkableeffectinthispatient,enablingsufficientandfavorablehearingrecoverysuchastoallowthepatienttoengageindailyconversations.Per-rotatorynystagmuswasrecordedonanelectronystagmogramforbothrightandleftrotationsinadampedrotationalchairtest.Itisrarefordeafchildrenwithseverebilateralinnerearmalformationtodemonstratefavorabledevelopmentinhearingandgoodequilibriumfunction.OurfindingssuggestthatauditoryevestibularhaircellsinthispatientmayhavebeenpartiallypreserveddespiteIP-Iintherightearandcommoncavitydeformityoftheleftear.

简介：<正>AttheinvitationofJapanNPO"theWorld"andPhilippineCenterofYoungLeadersinGovernance(PCYL),a6-memberCAFIUdelegationheadedbySecretary-GeneralNiJianpaidafriendlyvisittoJapanandthePhilippinesfromNovember1toNovember8.Duringthevisit,thedelegationhadextensivecontactsandexchangeswithpoliticians,NGOsandordinary

简介：AbstractBackground:Psoriasis is a chronic inflammatory skin disease, affecting about 0.6% of the Chinese population. Many patients are not well controlled by conventional treatments, thus there is need for new treatment regimens. In this study, we assessed the efficacy and safety of secukinumab in Chinese patients with moderate to severe plaque psoriasis.Methods:This study was a 52-week, multicentre, randomized, double-blind, placebo-controlled, parallel-group, Phase 3 trial. A sub-population of study participants (≥18 years) of Chinese ethnicity were randomized to receive subcutaneous injections of 300 or 150 mg secukinumab, or placebo. The co-primary endpoints were psoriasis area severity index (PASI) 75 and Investigator’s Global Assessment (IGA) 0/1 at Week 12.Results:A total of 441 Chinese patients were enrolled in this study. Co-primary outcomes were achieved; 300 and 150 mg secukinumab were superior to placebo as shown in the proportion of patients that achieved PASI 75 (97.7% and 87.2% vs. 3.7%, respectively; P < 0.001), and IGA 0/1 (82.3% and 69.7% vs. 2.7%; P < 0.001) at Week 12. Treatment efficacy was maintained until Week 52. There was no increase in overall adverse events with secukinumab relative to placebo throughout the 52-week period. Conclusion: Secukinumab is highly effective and well tolerated in Chinese patients with moderate to severe plaque psoriasis.Trial Registration:ClinicalTrials.gov, NCT03066609; https://clinicaltrials.gov/ct2/show/record/NCT03066609.